Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12926097 | 0.86 | NR3C2 (0.43) | KMT2ACYP19A1PTGS1PTGS2LMNA | |
| SCHEMBL13524327 | 0.84 | PTGS2 (0.75) | PTGS1PTGS2 | |
| SCHEMBL6723287 | 0.82 | PTGS2 (0.58) | CYP19A1PTGS1PTGS2 | |
| SCHEMBL6721384 | 0.81 | PTGS2 (0.51) | CYP19A1PTGS1PTGS2 | |
| SCHEMBL6739907 | 0.81 | PTGS2 (0.57) | PTGS1PTGS2 | |
| SCHEMBL26200506 | 0.80 | KMT2A (0.40) | KMT2ACYP19A1PTGS1PTGS2 | |
| SCHEMBL6739266 | 0.80 | PTGS2 (0.50) | KMT2APTGS1PTGS2 | |
| SCHEMBL9667604 | 0.79 | MAPT (0.49) | KMT2APTGS2SMN1; SMN2 | |
| SCHEMBL6340471 | 0.79 | PTGS1 (0.71) | KMT2ACYP19A1PTGS1PTGS2 | |
| SCHEMBL6350545 | 0.79 | KMT2A (0.56) | KMT2ACYP19A1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050131239-A1 | Preparation of aryl-substituted butenolides using mucohalic acids | BLAZECKA PETER G (CA) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131239-A1 | Preparation of aryl-substituted butenolides using mucohalic acids | DBH, BBOX1, ALG1 | KMT2A 2848/4885CYP19A1 935/4885PTGS1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.